Clinical Trials Logo

Lower Urinary Tract Symptoms clinical trials

View clinical trials related to Lower Urinary Tract Symptoms.

Filter by:

NCT ID: NCT00831233 Terminated - Prostate Cancer Clinical Trials

Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Start date: April 2009
Phase: Phase 3
Study type: Interventional

The purpose of this trial was to see how well a new trial drug (degarelix) worked on lower urinary tract symptoms (also known as LUTS) in prostate cancer patients as compared to how a standard drug hormonal treatment worked on the same symptoms. The advancement/worsening of prostate cancer may be associated with LUTS and the symptoms may impact the ability to urinate normally and thereby the quality of life for these patients. Patients were randomly selected (like flipping a coin) to receive either degarelix or standard hormone therapy (combination of goserelin and bicalutamide) for a 3 month treatment period. During this period the relief of urinary symptoms was evaluated via a questionnaire filled in by patients and addressing the severity and frequency of their symptoms.

NCT ID: NCT00743184 Terminated - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

Start date: December 4, 2008
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in men as assessed by the International Prostate Symptom Score (IPSS) at Week 14.

NCT ID: NCT00501371 Terminated - Clinical trials for Benign Prostatic Hyperplasia

MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

Start date: July 2007
Phase: Phase 3
Study type: Interventional

Phase III, Randomized, double-blind, parallel placebo-controlled study. Two arms: MCS (30mg/day) vs. placebo. Subproject MCS-2: alpha-blocker naïve subjects Subproject MCS-3: subjects responding poorly to alpha-blocker

NCT ID: NCT00116571 Terminated - Clinical trials for Prostatic Hyperplasia

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

Start date: May 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate. Photodynamic therapy (known as "PDT") is a treatment that uses light to make a drug work. This means the drug is "light-activated". Light-activated drugs do not work until a certain color of light shines on the drug. When the drug and the light combine, they react together to destroy tissue. This study is investigating PDT with lemuteporfin as a possible treatment for an enlarged prostate. PDT with lemuteporfin may destroy overgrown prostate tissue and help urinary symptoms go back to normal.